Pfizer (PFE) Announces IBRANCE Phase 3 PALOMA-3 Met Primary Endpoint
Tweet Send to a Friend
Pfizer (NYSE: PFE) announced that the Phase 3 PALOMA-3 trial for IBRANCEĀ® (palbociclib) met its primary endpoint of demonstrating an ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE